[
  {
    "Company": "HUB Organoids",
    "Model": "Healthy Intestinal Organoid",
    "Organs/Tissues": "Human small or large intestine (epithelium)",
    "Physiological/Pathological": "Physiological (healthy epithelium)",
    "Cell Source": "Primary adult stem cells (Lgr5+) from healthy intestinal biopsies",
    "Multiple Cell Types": "Yes, multiple epithelial lineages (enterocytes, goblet, etc.)",
    "Stromal Cells": "No by default (pure epithelial organoid), fibroblasts can be co-cultured optionally",
    "Tissue-resident Immune": "No by default (added in co-culture if needed)",
    "Circulating Immune": "No (can introduce PBMCs in advanced co-cultures)",
    "Crosstalk (Multi-tissue)": "No single model; can be combined with other organoids or microbes in co-culture",
    "Air-Liquid Interface": "Possible in 2D organoid-derived monolayer on Transwell",
    "Extracellular Matrix": "Yes (Matrigel or BME for 3D organoid growth)",
    "3D Scaffold": "Yes (hydrogel dome). Can do 2D monolayer for barrier assays",
    "Notable Features": "Long-term expansion, stable genotype, full intestinal differentiation, used for normal GI function & toxicity",
    "Plate/Format (Throughput)": "Commonly 24- or 96-well plates, can scale to 384-well for screening",
    "Max Culture Duration": "Indefinite passaging (stable lines), each assay typically 7+ days",
    "Readouts - Live Imaging": "Yes (brightfield, confocal)",
    "Readouts - Supernatant Sampling": "Yes (secreted factors, e.g. IL-8)",
    "Readouts - Cell Retrieval": "Yes (enzymatic dissociation for flow, -omics)",
    "Readouts - Whole Tissue": "Yes (fix organoids, IHC/IF on sections or whole-mount)",
    "Readouts - TEER": "Yes (if using monolayer Transwell setup)",
    "Readouts - MEA": "No",
    "Readouts - Integrated Biosensors": "No (external measurement methods)",
    "Dead Volume": "Minimal (small Matrigel domes + small media volume)",
    "Perfused": "Not typically (static culture); can integrate with microfluidics if desired",
    "Gas Mix Controlled": "Standard incubator (5% CO₂)",
    "Real-time Microenvironment Control": "Manual media changes, can add stimuli or immune cells, no dynamic flow",
    "model_availability": "Both (service at HUB or technology license)"
  },
  {
    "Company": "HUB Organoids",
    "Model": "Cystic Fibrosis Intestinal Organoid",
    "Organs/Tissues": "Patient-derived intestinal epithelium (CFTR mutation)",
    "Physiological/Pathological": "Pathological (genetic CF), can test CFTR modulators",
    "Cell Source": "Rectal biopsy from CF patients → CF organoids",
    "Multiple Cell Types": "Yes, multiple epithelial lineages but all from CF patient’s tissue",
    "Stromal Cells": "No (pure epithelial organoid), optional co-culture",
    "Tissue-resident Immune": "No by default",
    "Circulating Immune": "No by default",
    "Crosstalk (Multi-tissue)": "No single model; can do advanced co-cultures or microbe co-culture",
    "Air-Liquid Interface": "Possible in monolayer format, typically 3D submerged",
    "Extracellular Matrix": "Yes (Matrigel/BME)",
    "3D Scaffold": "Yes (organoids in a gel dome)",
    "Notable Features": "Forskolin-induced swelling assay (functional readout of CFTR), personalized drug response correlation",
    "Plate/Format (Throughput)": "Commonly 48/96-well for swelling assay, scalable to higher",
    "Max Culture Duration": "Indefinite expansion, used in short-term (days) swelling tests",
    "Readouts - Live Imaging": "Yes (tracking organoid size changes in real time)",
    "Readouts - Supernatant Sampling": "Yes (analyzing secreted factors if needed)",
    "Readouts - Cell Retrieval": "Yes (end-point digestion for molecular profiling)",
    "Readouts - Whole Tissue": "Yes (fix & stain for CFTR or other markers)",
    "Readouts - TEER": "Only if grown as monolayer, typically not for swelling assay",
    "Readouts - MEA": "No",
    "Readouts - Integrated Biosensors": "No, external imaging for swelling quantification",
    "Dead Volume": "Minimal (small culture volumes)",
    "Perfused": "No, usually static culture",
    "Gas Mix Controlled": "Incubator-based (5% CO₂)",
    "Real-time Microenvironment Control": "Manual addition of CFTR modulators, imaging swelling in real-time",
    "model_availability": "Both (HUB service or license to CF organoids, widely used clinically)"
  },
  {
    "Company": "HUB Organoids",
    "Model": "Patient-Derived Tumor Organoid (e.g. Colorectal Cancer)",
    "Organs/Tissues": "Human tumor epithelium (colon cancer, etc.)",
    "Physiological/Pathological": "Pathological (patient tumor) maintaining original mutations",
    "Cell Source": "Tumor biopsy → cancer stem cells grown as organoids",
    "Multiple Cell Types": "Multiple epithelial tumor subclones, no stromal/immune by default",
    "Stromal Cells": "No (pure tumor epithelium); fibroblasts can be co-cultured if needed",
    "Tissue-resident Immune": "No by default, immune cells removed during organoid derivation",
    "Circulating Immune": "No by default, can add T cells for immunotherapy assays",
    "Crosstalk (Multi-tissue)": "Not typically, single tumor organoid system. Possible combination with other organoids",
    "Air-Liquid Interface": "No (3D submerged in matrix), can do monolayers for certain assays",
    "Extracellular Matrix": "Yes (Matrigel/BME to support tumor organoid growth)",
    "3D Scaffold": "Yes (tumor spheroids in 3D gel)",
    "Notable Features": "Preserves patient-specific tumor mutations, drug response correlates with clinical outcomes",
    "Plate/Format (Throughput)": "Up to 384-well for screening, or lower for complex assays",
    "Max Culture Duration": "Stable indefinite passaging, typical assay 7–14 days",
    "Readouts - Live Imaging": "Yes (monitor tumor growth, viability, morphological changes)",
    "Readouts - Supernatant Sampling": "Yes (secreted biomarkers, e.g. CEA)",
    "Readouts - Cell Retrieval": "Yes (enzymatic dissociation for molecular, genomic analyses)",
    "Readouts - Whole Tissue": "Yes (fix entire organoid, histology for proliferation/apoptosis)",
    "Readouts - TEER": "No, not a barrier model",
    "Readouts - MEA": "No",
    "Readouts - Integrated Biosensors": "No, external imaging and viability assays",
    "Dead Volume": "Minimal",
    "Perfused": "No standard perfusion; can integrate microfluidics if advanced",
    "Gas Mix Controlled": "Incubator-based",
    "Real-time Microenvironment Control": "Can add drugs, immune cells, etc.; no continuous flow in default model",
    "model_availability": "Both (HUB drug screening services or license for internal use)"
  },
  {
    "Company": "HUB Organoids",
    "Model": "Inflammatory Bowel Disease (IBD) Organoid + Immune Co-culture",
    "Organs/Tissues": "Intestinal epithelium from IBD patient + immune/stromal cells",
    "Physiological/Pathological": "Pathological (inflammatory GI epithelium), recapitulating IBD",
    "Cell Source": "Patient with IBD → adult stem cell–derived epithelial organoids + optionally fibroblasts, immune cells",
    "Multiple Cell Types": "Yes (epithelium + fibroblasts + T cells), advanced co-culture",
    "Stromal Cells": "Yes (IBD fibroblasts co-cultured for inflammatory environment)",
    "Tissue-resident Immune": "No (original organoid is epithelial), added ex vivo immune cells",
    "Circulating Immune": "Yes, can add PBMCs/T-cells from patient or healthy donor",
    "Crosstalk (Multi-tissue)": "Not typically, but epithelial-immune-stromal interactions are in one culture",
    "Air-Liquid Interface": "Possible in Transwell monolayer format with co-culture compartments",
    "Extracellular Matrix": "Yes (Matrigel for organoid 3D, or monolayer on coated inserts)",
    "3D Scaffold": "Yes if using 3D; 2D if using ALI co-culture. Both are possible",
    "Notable Features": "Simulates IBD inflammatory responses (cytokines, barrier disruption), host-microbe co-cultures also feasible",
    "Plate/Format (Throughput)": "Lower throughput (24- or 96-well) due to complexity",
    "Max Culture Duration": "Weeks possible, with repeated immune stimulation",
    "Readouts - Live Imaging": "Yes, to see barrier integrity, immune infiltration",
    "Readouts - Supernatant Sampling": "Yes (cytokines, e.g. TNF-α, IL-8)",
    "Readouts - Cell Retrieval": "Yes (dissociate co-culture for flow cytometry of immune activation)",
    "Readouts - Whole Tissue": "Yes (fix & stain epithelium, fibroblasts, immune cells)",
    "Readouts - TEER": "Yes if using monolayer Transwell, measuring barrier function",
    "Readouts - MEA": "No",
    "Readouts - Integrated Biosensors": "No, external assays for inflammation/ barrier readouts",
    "Dead Volume": "Minimal (small volumes in well-based co-culture)",
    "Perfused": "No standard, static culture with media changes (custom microfluidics possible)",
    "Gas Mix Controlled": "Incubator-based",
    "Real-time Microenvironment Control": "Manual addition of inflammatory stimuli, media changes, no continuous flow",
    "model_availability": "Both (HUB service or license). Complex co-culture is advanced offering"
  }
]
